|
Geron Corporation Announces Issuance of U.S. Patent for Pig Cloning via COMTEX April 16, 2003 MENLO PARK, Calif., Apr 16, 2003 (BUSINESS WIRE) -- Geron Corporation (Nasdaq:GERN) announced today that it has been issued U.S. Patent No. 6,548,741, describing an improved method for cloning pigs. The inventors include some of the original scientists at the Roslin Institute in Edinburgh, Scotland, who cloned Dolly the sheep. The new patent teaches how the Dolly method can be adapted to clone pigs more efficiently by maturing the recipient pig oocyte using defined culture conditions. The patented new method results in cloned pig embryos with improved developmental potential. This is the first U.S. patent assigned directly to Geron Corporation relating to animal cloning. Geron also owns exclusive rights to the Roslin patents (U.S. Patent Nos. 6,147,276, 6,252,133 and 6,525,243), which cover the fundamental nuclear transfer technology used in cloning animals. Thomas B. Okarma, Ph.D., M.D., Geron`s president and chief executive officer, explained, `We entered into the collaboration with the Roslin Institute in order to develop and consolidate the field of animal cloning, as well as to support our regenerative medicine program. Cloned pigs are of interest because of their potential to provide much needed organs for xenotransplantation. This new patent is an important addition to our nuclear transfer intellectual property portfolio. It improves prospects for commercialization of the cloning process for pigs. We have licensed rights or granted options to the fundamental cloning process to six companies, and are in discussions with others regarding additional licenses.` Professor John Clark, at the Roslin Institute, said, `This patent adds to the nuclear transfer portfolio initially generated at the Roslin Institute and enhanced in collaboration with Geron Corporation. Xenotransplantation has important medical potential. The patented new methods enhance the likelihood of commercially successful organ replacement therapies.` Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine, and research tools for drug discovery. Geron`s product development programs are based upon three patented core technologies: telomerase, human embryonic stem cells, and nuclear transfer. This news release may contain forward-looking statements made pursuant to the `safe harbor`provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding future applications of Geron Corporation`s technology constitute statements involving risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products and the maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron`s periodic reports, including the annual report on Form 10-K for the year ended December 31, 2002. Geron Corporation David L. Greenwood, 650/473-7765 (Investor and Media Relations) http://www.businesswire.com Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page. Copyright (C) 2003 Business Wire. All rights reserved. JS200 |
|
| aus der Diskussion: | Geron mit Hammernews!! |
| Autor (Datum des Eintrages): | js200 (16.04.03 13:34:40) |
| Beitrag: | 93 von 3,090 (ID:9188508) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |